Original language | English |
---|---|
Pages (from-to) | 3537-3538 |
Number of pages | 2 |
Journal | Psychopharmacology |
Volume | 234 |
Issue number | 23-24 |
DOIs | |
Publication status | Published - 01-12-2017 |
All Science Journal Classification (ASJC) codes
- Pharmacology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Psychopharmacology, Vol. 234, No. 23-24, 01.12.2017, p. 3537-3538.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Response to the letter from Dr. Veerman and colleagues
AU - Kishi, Taro
AU - Ikuta, Toshikazu
AU - Matsuda, Yuki
AU - Iwata, Nakao
N1 - Funding Information: Conflict of interest Drs. Kishi, Ikuta, Matsuda, and Iwata declare that they have no direct conflicts of interest relevant to this study. Dr. Kishi has received a speaker’s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Otsuka, Meiji, MSD, Tanabe-Mitsubishi (Yoshitomi), and Pfizer, and has a Health Labor Sciences Research Grant and a Fujita Health University School of Medicine research grant. Funding Information: We thank Dr. S. R. T. Veerman (Mental Health Service Organization North Holland North, Community Mental Health Division, Flexible Assertive Community Treatment, Alkmaar, The Netherlands) and Dr. David de Lucena (rograma de P?s-Gradua??o, em Medicina: Psiquiatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil) for providing information for this study. Drs. Kishi, Ikuta, Matsuda, and Iwata declare that they have no direct conflicts of interest relevant to this study. Dr. Kishi has received a speaker?s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Otsuka, Meiji, MSD, Tanabe-Mitsubishi (Yoshitomi), and Pfizer, and has a Health Labor Sciences Research Grant and a Fujita Health University School of Medicine research grant. Dr. Ikuta has received speaker?s honoraria from Eli Lilly, Daiichi Sankyo, and Dainippon Sumitomo. Dr. Matsuda has received speaker?s honoraria from Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Otsuka, Tanabe-Mitsubishi and Pfizer, and has a Grant-in-Aid for Young Scientists (B). Dr. Iwata has received speaker?s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer, and had research grants from GlaxoSmithKline, Meiji, and Otsuka.
PY - 2017/12/1
Y1 - 2017/12/1
UR - http://www.scopus.com/inward/record.url?scp=85030664884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030664884&partnerID=8YFLogxK
U2 - 10.1007/s00213-017-4757-8
DO - 10.1007/s00213-017-4757-8
M3 - Letter
C2 - 28988381
AN - SCOPUS:85030664884
SN - 0033-3158
VL - 234
SP - 3537
EP - 3538
JO - Psychopharmacology
JF - Psychopharmacology
IS - 23-24
ER -